NCT05660616CompletedPhase 2
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Switch-Maintenance Gemcitabine After First-Line Chemotherapy (Pemetrexed-Platinum) In Patients With Malignant Pleural Mesothelioma In Ain Shams University Hospitals
Source: ClinicalTrials.gov · Last updated 27 Aug 2024
Brief summary (registry, in English)
Mesothelioma is an aggressive form of cancer. Treatments are available, but for many people, a cure isn't possible. This thesis is to assess the efficacy and safety of switch-maintenance Gemcitabine in Mesothelioma patients after first line chemotherapy (Pemetrexed-Platinum)
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 5 Dec 2022
- Start date
- 1 Apr 2023
- Primary completion date
- 1 Apr 2024
- Lead sponsor
- Ain Shams University
- Diseases
- Mesothelioma, Lung cancer
- NCT number
- NCT05660616
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 40
- From 1 Apr 2023 to the primary completion date, 1 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are candidates for curative surgery
Other illness
- Progression of disease after first line
Other
- Pregnant females
- ECOG Performance 3-4
- Patients with sarcomatoid mesothelioma
Who the study is looking for
- Being at least 18 years old
- Histologically or cytologically confirmed unresectable malignant pleural mesothelioma
- ECOG Performance status 0-2
- Completed at least four cycles of first line platinum (cisplatin or carboplatin) and pemetrexed combination chemotherapy before study entry
- No evidence of disease progression following first-line treatment based on radiological criteria.
- Adequate organ function is mandatory, defined as haemoglobin of at least 8.5 mg/dl, platelets of at least 100×10⁹ per L, and neutrophils of at least 1×10⁹/L.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.